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cination coverage and epidemiology that quickly overrule varia-
tions due to discounting.
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decision analysis: a primer. Pharmacoeconomics 2011;29:371–86.Practical Implications of Differential Discounting of Costs and Health
Effects in Cost-Effectiveness AnalysisWe welcome Westra et al.’s comments on our recent article that
addressed the influence of the number of future cohorts on
cost-effectiveness estimates under differential discounting.
Their comments usefully illustrate some of the unresolved
questions regarding the correct implementation of differential
discounting.
Differential discounting is already recommended practice in
The Netherlands and Belgium and is also being used in a number
of other countries. The National Institute for Health and Clinical
Excellence in England and Wales recently recommended that
differential discounting be applied in a sensitivity analysis in
certain circumstances [1]. Therefore, understanding the practi-article intended to further develop that understanding, not op-
pose differential discounting.
Westra et al. contend that variation in cost-effectiveness esti-
mates due to the differences between studies in the numbers of
cohorts modeled is not arbitrary because the numbers of cohorts
modeled are not arbitrary but determined by the time horizon for
the implementation of the intervention. We did not claim in our
article that the number of cohorts modeled is arbitrary in any
general sense. We contend that if there is no clear and consistently
applied understanding of the appropriate number of cohorts to
include in CEAs then the actual number of cohorts modeled may
vary arbitrarily between studies. This is the situation as we see it
at present, evidenced by the large variation in the numbers of
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CEAs of human papillomavirus (HPV) vaccination included in a
recent review [2], all the static models include only one recipient
irth-year cohort (evidently shorter than the likely lifetime of use
f the vaccine), while the dynamic HPV transmission models in-
lude 50 or 100 vaccinated cohorts. It appears, in the case of HPV
accination, that modelers are not currently specifying their CEAs
ccording to the expected lifetime of the intervention, but either
ccording to the principle of parsimony in the case of static models
r by allowing the model sufficient time for disease incidence to
each a steady state in the case of dynamic models. Similar varia-
ion in the number of cohorts modeled can be found in the broader
EA literature beyond the specific example of HPV vaccination.
Westra et al. suggest that an intervention should be modeled
for the minimum period it will be in place. If this minimum period,
however, is different from the expected actual implementation
lifetime, then the resulting cost-effectiveness estimate will be
wrong, assuming that we want to estimate the intervention’s cost-
effectiveness over its entire lifetime.
A further question remains even if the numbers of future recipi-
ent cohorts are known with certainty and CEA models specified ac-
cordingly. Consider two interventions of identical cost-effectiveness
when assessed on a per-cohort basis, but with unequal expected
lifetimes of use. The intervention with the longer lifetime will be
more cost-effective when the two interventions are compared over
their respective lifetimes. How this difference between the per-co-
hort and lifetime perspectives for assessing cost-effectiveness re-
lates to decision making still needs further attention.
Westra et al. then describe how costs and effects could be
discounted not to a single discount year, but to the year in
which the intervention is started by each recipient cohort and
the results compared with the prevailing cost-effectiveness
threshold at that time. Essentially the suggestion is that cost-
effectiveness be judged on a per-cohort basis. We agree that as-
sessing cohorts separately might bring some useful clarity in cer-
tain cases. Considering cohorts separately, however, is not an
adequate solution in all cases, as multiple cohorts are required
where effectiveness is shared between cohorts over time, such as
in the case of infectious diseases, or where a technology is shared
by successive cohorts, such as a diagnostic imaging machine. Fur-
thermore, the results could be difficult to interpret if an interven-
tion that has benefits shared by many cohorts is found to be cost-
effective in some cohorts but not others: We still need some sort of
aggregate cost-effectiveness estimate to inform us whether the
intervention is worth undertaking.
We agree with Westra et al. that a dynamic model would be
more suitable for assessing HPV vaccination, especially when the
vaccination uptake is not very high. Our model, however, was toillustrate an important methodological point, for which we con-
sider it entirely appropriate. We firmly disagree with their state-
ment that other factors such as herd immunity “overrule” varia-
tions due to discounting. Our article estimated a 26% reduction in
the incremental cost-effectiveness ratio of HPV vaccination with
the inclusion of future cohorts over 30 years, demonstrating the
very significant influence that discounting can have on cost-effec-
tiveness ratios. This influence of discounting will be in addition to
other factors such as herd immunity, not subordinate to them.
Finally, we would like to reemphasize that our article is not
opposed to differential discounting but calls for both greater un-
derstanding of its impact under different model structures and
clearer guidance to ensure models adequately correspond to the
policy questions they are to inform.
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